United States

People: Celgene Corp (CELG.O)

CELG.O on Nasdaq

1:13pm EDT
Change (% chg)

$2.30 (+1.86%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Daniel, Thomas 

Dr. Thomas O. Daniel, M.D., serves as Chairman - Celgene Research of the Company. He was the President - Research and Early Development of Celgene Corp. He served as the Chief Scientific Officer and Director at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics since September 2003. Dr. Daniel served as Vice President, Research at Amgen Inc., where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Prior to Amgen’s acquisition of Immunex, Dr. Daniel served as Senior Vice President of Discovery Research. Dr. Daniel has been a member of the Therapeutic Advisory Board of aTyr Pharma, Inc. since March 1, 2011, is a director of Ferrumax and Epizyme, privately-held biotechnology companies. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He formerly conducted research in the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.

Basic Compensation

Total Annual Compensation, USD 3,792,520
Restricted Stock Awards, USD 1,969,450
Long-Term Incentive Plans, USD --
All Other, USD 1,580,010
Fiscal Year Total, USD 7,341,980

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 76,364 5,374,780.00
Name Fiscal Year Total

Robert Hugin


Jacqualyn Fouse


Mark Alles


Peter Kellogg


Thomas Daniel


Scott Smith

As Of  30 Dec 2015